Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
541-560 of 2,251 trials

High-Risk Aggressive B-Cell Lymphomas: R-Hyper-CVAD/R-MA Treatment

We are studying a new treatment approach for patients with high-risk aggressive B-cell lymphomas to see if it is effective and safe. This trial aims to improve outcomes for those facing this serious condition.

Lymphoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

HMB-001 for Glanzmann Thrombasthenia

We are investigating a new treatment to see if it is safe and can help reduce bleeding in people with Glanzmann Thrombasthenia. This study will also look at how the body processes the medication and its effects on quality of life.

Glanzmann's Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Juvenile Psoriatic Arthritis: Risankizumab Study

We are studying a new treatment called risankizumab for children aged 5 to 17 with active juvenile psoriatic arthritis. The goal is to see if it is safe and effective compared to an existing medication.

Juvenile Psoriatic Arthritis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyPediatricsRheumatology

DIPG Treatment Study: ONC201 vs. Everolimus

We are testing a new drug, ONC201, for children with newly diagnosed DIPG and related tumors. The goal is to see if it helps improve survival and progression-free time compared to standard treatment.

Brain Stem Glioma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Hypertonic Lactate After Cardiac Arrest: The LATTE Trial

We are studying whether hypertonic sodium lactate can help reduce brain injury in comatose survivors of cardiac arrest. This trial will also look at its effects on recovery and safety.

Cardiac ArrestComaPost Cardiac Arrest Syndrome≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyNeurology

Follicular Lymphoma: Mosunetuzumab and Zanubrutinib Study

We are investigating a combination of two medications for patients with relapsed or refractory follicular lymphoma. The goal is to see if this treatment improves outcomes and safety compared to existing options.

Follicular Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Ketamine for Depression and Alcohol Use Disorder

We are studying whether ketamine can help adults with depression and alcohol use disorder during their addiction treatment. The trial will also look at the safety of this treatment approach.

DepressionAlcohol Use Disorder6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Pain Management: Dexmedetomidine for Nerve Block

We are exploring the best dose of dexmedetomidine to enhance pain relief during a nerve block procedure. This study will also check for side effects and benefits like reduced opioid use and better patient satisfaction.

Patients Scheduled for Shoulder Operations1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOrthopedics and TraumatologyOtolaryngology

Gastric Cancer: Dostarlimab Immunotherapy Study

We are exploring a new treatment approach for patients with localized gastric cancer to see if delaying surgery while using Dostarlimab can be effective. The study aims to evaluate patient responses and safety over time.

Metastatic Gastric Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Colorectal Cancer: Reduced Dose Chemotherapy for Older Patients

We are studying whether a lower dose of chemotherapy is as effective as the standard dose for older patients with advanced colorectal cancer. This may help improve quality of life and reduce severe side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Cerebral Amyloid Angiopathy: New Treatment Approaches

We are studying whether non-invasive vagus nerve stimulation and low-sodium oxybate can help clear amyloid-beta from the brain in patients with cerebral amyloid angiopathy. This research aims to improve understanding of potential treatments for this condition.

Cerebral Amyloid Angiopathy≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Juvenile Idiopathic Arthritis: Baricitinib Study

We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.

Juvenile Idiopathic Arthritis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Breast Reconstruction: Goal-Directed Fluid Therapy

We are studying how a specific fluid management approach during DIEP breast reconstruction may reduce swelling and improve healing. This trial aims to see if it helps with better blood flow to the surgical area.

Low Blood Pressure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal MedicineOtolaryngology

Efgartigimod PH20 SC for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will help us understand the right dose and evaluate its safety and effects on daily life.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Atopic Dermatitis: Personalized Treatment Approaches

We are studying how genetic and biochemical markers can help choose the best treatment for patients with atopic dermatitis needing stronger therapies. This research may lead to better management strategies tailored to individual needs.

Atopic Dermatitis6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesAllergologyDermatology

GHB Use Disorder: Baclofen Treatment Study

We are testing whether adding baclofen can help reduce the need for GHB during detox for patients with GHB use disorder. This study aims to improve the detox process for those seeking recovery.

GHB Use DisorderEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Neonatal OTC Deficiency: ECUR-506 Treatment Study

We are investigating a new treatment called ECUR-506 for boys under 9 months with neonatal onset OTC deficiency. The study will help us understand its safety and how well it works.

Ornithine Transcarbamylase Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

Chronic Spontaneous Urticaria: Omalizumab Treatment Intervals

We are studying whether adults with well-controlled chronic spontaneous urticaria can safely extend the time between omalizumab treatments while maintaining symptom control.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Colorectal Liver Metastases: HAIP-SYST Treatment Study

We are investigating a new combination of local and systemic chemotherapy for patients with initially unresectable colorectal liver metastases. The study aims to see if this approach improves survival and quality of life compared to standard treatment.

Colorectal Liver Metastases1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHepatologyOncology

Carbetocin Nasal Spray for Hunger in Prader-Willi Syndrome

We are studying the safety of carbetocin nasal spray for people with Prader-Willi Syndrome who experience uncontrollable hunger. The trial also looks at how this treatment may help with anxiety and caregiver challenges.

Hyperphagia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyPediatrics